BD, IACC and Mayapada Healthcare Launch Initiative to Boost Laboratory Accuracy in Indonesia

The collaboration will focus on conducting observation-based preanalytical quality checks aligned with international guidelines and best practices, including those from Clinical and Laboratory Standards Institute (CLSI) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM). This initiative seeks to identify gaps in specimen collection and handling practices and provide actionable insights to reduce diagnostic errors and enhance patient safety.

 A key differentiator of this collaboration is the Fulcrum assessment platform, which enables comprehensive evaluations and generates detailed reports to guide quality improvement allows benchmarking from other assessment results in Indonesia and other countries. Preanalytical errors account for up to 70% of laboratory mistakes, making them the leading cause of diagnostic inaccuracies (Plebani, M., Clin Chem Lab Med, 2006).  

This collaboration will enable Mayapada Healthcare access to a data-driven roadmap to address preanalytical diagnostic error, ensuring that Indonesian patients get the right diagnosis the first time. By addressing these gaps, the MIHYC program aims to improve patient safety, enhance laboratory efficiency, and support Indonesian government’s Health Transformation Agenda, Medium-Term National Development Plan (RPJMN) 2025–2029.

Dr. Dennis Jacobus, SpK, Head of Mayapada Laboratory Network of Mayapada Healthcare said, “The collaboration will focus on conducting observation-based pre-analytical quality checks aligned with international guidelines and best practices, including those from the Clinical and Laboratory Standards Institute (CLSI) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), to identify gaps in specimen collection and handling practices and provide actionable insights to reduce diagnostic errors and enhance patient safety. Through this strategic initiative, the partnership strengthens the most critical phase of laboratory testing by driving standardized practices, enhancing healthcare professionals’ competencies, optimizing workflows across service units, and ultimately delivering greater diagnostic accuracy, reduced error risks, faster turnaround times, and more consistent, evidence-based results to support precise clinical decision-making for patients.”

“Strong pre-analytical practices build a pathway to reliable diagnostics. At IACC, we are committed to empowering every laboratory professional to perform the entire process correctly, in accordance with guidelines from the very first step, especially in the preanalytical phase,” added Dr. Lia Gardenia Partakusuma, Sp. PK(K), MM, MARS, FAMM, President of the Indonesian Association for Clinical Chemistry (IACC).

“This collaboration demonstrates BD’s commitment to driving innovation in healthcare. By applying global expertise and advanced solutions, we aim to help laboratories adopt international standards, reduce diagnostic errors, and improve overall quality. Working with Mayapada Healthcare and IACC, we are contributing to Indonesia’s Health Transformation Agenda and strengthening laboratory practices across the region,” said Lu Liang, Vice President and General Manager, BD Southeast Asia.

# # #

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease, and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety, and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo, or Instagram @becton_dickinson

Contact:
Media
Rizka Laksmi
Head of Communications BD Southeast Asia 
rizka.laksmi@bd.com

About Mayapada Healthcare

Mayapada Healthcare (PT Sejahteraraya Anugrahjaya Tbk.) (Ticker Code: SRAJ) is a key business pillar of Mayapada Group (founded by Dato' Sri Prof. DR. Tahir in 1986) in the healthcare services sector, operating seven hospitals with over 1,200 beds and more than 1,500 professional medical teams. Mayapada Hospital has received various accreditations and awards, as well as 11 'Centers of Excellence'. The seven hospitals under Mayapada Healthcare are Mayapada Hospital Tangerang, Mayapada Hospital South Jakarta, Mayapada Hospital Bogor, Mayapada Hospital Kuningan, Mayapada Hospital Surabaya, Mayapada Hospital Bandung, and Mayapada Hospital Nusantara. The 11 'Centers of Excellence' at Mayapada Hospital include: Tahir Neuroscience Center, Tahir Uronephrology Center, Cardiovascular Center, Gastrohepatology Center, Oncology Center, Orthopedic Center, Obstetrics & Gynecology Center, Pediatric Center, Internal Medicine and Pulmonology Center, Allergy-Immunology Center, and the Mayapada Autoimmune Center Indonesia, the first and only autoimmune service center in Indonesia.

Click here for Indonesian version